 For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the SP 500 index, Wedbushs Laura Chico said Wednesday on PreMarket Prep Plus. Chico, the senior vice president of biotech equity research at the analyst firm, said she attributes the underperformance to a few factors. 